Zelluna Submits First CTA for MAGE-A4-Targeting TCR-NK Therapy
Event summary
- Zelluna submitted its first Clinical Trial Application (CTA) to the UK MHRA for ZI-MA4-1 on 17 December 2025.
- First GMP batch of ZI-MA4-1 was manufactured and quality-tested on 12 December 2025.
- NOK 58.2 million raised in November 2025 through private placement and retail offering.
- Total operating expenses for Q4 2025 were NOK 35.4 million, with a total loss of NOK 34.6 million.
- Cash position of NOK 78.3 million as of 31 December 2025, providing runway into Q1 2027.
The big picture
Zelluna's CTA submission for ZI-MA4-1 marks its transition to a clinical-stage company, positioning it in the rapidly evolving off-the-shelf cell therapy landscape. The successful submission and GMP manufacturing completion are critical milestones that could attract further investment and strategic partnerships. The company's focus on solid tumors with its TCR-NK platform addresses a significant unmet need in oncology, potentially differentiating it from competitors.
What we're watching
- Regulatory Approval
- Whether the UK MHRA will approve the CTA for ZI-MA4-1 and the timeline for initiation of the Phase I clinical trial (ZIMA-101).
- Clinical Data
- The pace at which initial Phase I clinical data for ZI-MA4-1 will emerge from mid-2026 and their potential impact on the company's valuation.
- Cash Burn
- How Zelluna will manage its cash burn rate to extend its runway beyond Q1 2027, given its current financial position.
Related topics